We are glad to report that in a recently published EMBO Journal...
Leadartis has participated in BioSpain 2018 held in Seville, Spain (September, 25-27th). BioSpain, the most important biotechnology event in Spain and one of the most highly regarded internationally, was chosen to reveal the immuno-oncology (IO) antibody programs to the investment community.
LeadArtis´scientists, in collaboration with other prime research institutions, have developed a new tactic to generate multispecific T-cell recruiting antibodies to eradicate cancers.
The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom. LeadArtis is a partner in the Immunostimulatory Agonist Antibodies for Cancer Therapy effort, a 6.9M€ funding initiative which incorporates long-standing expertise in agonist immunostimulatory antibodies (IS-Abs) from research institutions and small-medium enterprises (SEM) in five European countries (Germany, Italy, Spain, Sweden and United Kingdom).
Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for Degenerative Retina Diseases) project funded by the Spanish Ministry of Economy and Competitiveness (MINECO) under the RETOS program. The aim of TERET was the development of the next generation of angiogenic blockers where new compounds with greater efficacy and reduced side effects without compromising eye visual acuity of the patients are essential.
The third IACT review meeting took place on October 25-26, 2016 in Frankfurt, Germany. LeadArtis is a partner in the Immunostimulatory Agonist Antibodies for Cancer Therapy effort, a 6.9M€ funding initiative which incorporates long-standing expertise in agonist immunostimulatory antibodies (IS-Abs) from research institutions and small-medium enterprises (SEM) in five European countries (Germany, Italy, Spain, Sweden and United Kingdom).
LeadArtis announces the initiation of the IMAB project (Cancer immunotherapy with bispecific antibodies) funded by the Centre for Industrial Technology Development (CDTI) under the recently launched PID Excellence Program. The CDTI’s Project Excellence driver acknowledges highly regarded technologies and provides with top financing conditions.
LeadArtis is proud to announce its participation as coordinator of the IBIMAB project (Cancer immunotherapy with bispecific costimulatory antibodies) funded by the Spanish Ministry of Economy and Competitiveness (MINECO) under the RETOS 2016 Collaboration program. IBIMAB counts with collaborators such as the internationally regarded research institutions: Centro de Investigación Médica Aplicada-CIMA (Pamplona, Spain), Hospital Universitario Puerta de Hierro-HUPH (Madrid, Spain) and Instituto de investigaciones biomédicas Alberto Sols-IIBm-CSIC (Madrid, Spain).
Leadartis will participate in BioSpain 2016 to be held in Bilbao, Spain (September 28-30th). BioSpain was chosen to present our business to the investment community since is the most important biotechnology event in Spain and one of the most important internationally. LeadArtis will announce its business strategy at the highly regarded investment forum.
In collaboration with prominent academic institutions (Aarhus University, CIC bioGUNE, Parc de Recerca Biomèdica and Molecular Immunology Unit, Hospital Universitario Puerta de Hierro), LeadArtis´scientists have developed a new approach to generate mono and multispecific antibodies by fusing single-domain antibodies from camelid heavy-chain-only immunoglobulins (VHHs) to the human collagen XVIII trimerization domain (TIEXVIII).
The Ministry of Economy and Finance of the Community of Madrid (MEFCAM), following the recommendations of the European Union, has established the regional strategy for research and innovation for smart specialization of the Community of Madrid framework (hereinafter RIS3) to support the development of highly specialized innovating companies with a requirement of permanent competitiveness.
SARS-CoV-2 Spike Trimerbody could represent a therapeutic option for COVID-19.
14-10-2021
We are glad to report that in a recently published EMBO Journal... |
"Tumor-targeted costimulatory trimerbodies for cancer Immunotherapy”- A brief discussion with Juan Perez Villar, CEO, LEADARTIS.
07-06-2021
... |
Diario ABC España y Cadena Cope: Investigadores crean un nuevo anticuerpo antitumoral más eficaz
01-06-2021
El director de la unidad de inmunoterapia del cáncer del Instituto de Investigación del Hospital... |